This site is intended for health professionals only
Wednesday 19 December 2018
Share |

Topic: Latest News

December 6, 2018
Delays in taking new cancer drugs through clinical trials and getting them approved for use mean NHS patients are waiting longer to access them, a report by the Institute of Cancer Research (ICR) finds.

NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a new report has revealed.
The average time from when a cancer drug is patented to approval by NICE increased from 12.7 years between 2000-08 to 14.1 years between 2009-16, The Institute of Cancer Research, London (ICR) found.

December 6, 2018
Research shows 31% of medication administration errors in English and Welsh acute care trusts are due to omitted medicine or ingredient.

Three in 10 drug-related deaths occurring in acute care settings are caused by omission, a study has revealed.
 

December 6, 2018
Leading academics and health data specialists have formed an alliance to boost science and innovation in the UK

The UK’s leading academics and health data specialists have formed an alliance to develop new ways to design and support the medical research of the future, and to improve the care patients receive from the NHS.
 
The UK Health Data Research Alliance will look atthe best ways to design, use, collect, manage and analyse health data in a responsible way for clinical trials, medical research, and innovation.
 

November 29, 2018
First child cancer patients treated with new CAR-T therapy in UK

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

November 29, 2018
In the EU, regorafenib is indicated for treatment of adult patients with advanced unresectable hepatocellular carcinoma who have been previously treated with sorafenib
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Stivarga® (regorafenib) as an option for treating advanced unresectable hepatocellular carcinoma (HCC) in adults who have had Nexavar® (sorafenib) only if patientshave Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.1
 
November 29, 2018
A survey of people working within pharmaceutical industry within and outside the UK found growing negativity about the impact of Brexit on the UK healthcare sector

The majority of pharmaceutical professionals now say Brexit will have a negative impact on the UK healthcare sector, a survey has revealed.
 
Negative sentiment amongst healthcare professionals about the impact of Brexit on the UK healthcare sector has increased over the last three months, according to data and analytics company GlobalData.

November 28, 2018
Data from the ALTA trial showed sustained systemic and intracranial efficacy results and a manageable safety profile, leading to the longest progression-free survival and overall survival reported in this setting

Takeda has announced that the European Commission (EC) granted marketing authorisation for Alunbrig (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

 

The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on 20 September, 2018. 

 

November 27, 2018
NHS on track to make £300m in savings after adalimumab deals

The NHS is on track to make record savings of £300m after negotiating deals on low cost versions of the health service’s most expensive drug.

 

Deals with five manufacturers have been made to on biosimilar versions of adalimumab. The drug is used to treat 46,000 patients with conditions including rheumatoid arthritis, inflammatory bowel disease and psoriasis.

 

The savings will mean hospitals will pay around a quarter of the amount they usually spend on adalimumab, which is over £400m each year.

 

November 22, 2018
The amount of money medicines cost the NHS has more than doubled in less than 10 years, official figures have revealed

The amount of money medicines cost the NHS has more than doubled in less than 10 years, official figures have revealed.
 

November 22, 2018
AR101 slowly builds up tolerance to peanut allergy, study finds

A new oral biologic drug could reduce the risk of allergic reaction in children and adolescents following accidental peanut exposures, research has shown.
 

November 20, 2018
Galcanezumab is a humanised monoclonal antibody that binds to the calcitonin gene-related peptide, which plays a role in migraine attacks, blocking its downstream function

Eli Lilly and Company has announced that the European Commission (EC) has granted marketing authorisation for Emgality® (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month.1

 

November 20, 2018
Despite current recommended safe handling procedures, the potential for the exposure of healthcare providers to cytotoxic and hazardous drugs remains. Preventing workplace contamination is the best strategy to minimise cytotoxic drug exposure and the use of closed system transfer devices, alongside other protective measures, plays an important role

Cytotoxic and hazardous drug compounding is a technical challenge because it is necessary to implement correct aseptic technique to maintain product sterility while also minimising potential occupational and environmental exposure owing to the deleterious effects of this class of drugs.1

 

November 19, 2018
NHS trusts face staff shortage of more than 350,000 by 2030, think tanks warn

The NHS could have more than 350,000 vacancies by 2030 if emerging workforce trends continue, three healthcare think tanks have said.
 
The health care workforce in England: make or break?, jointly published today by The King’s Fund, the Health Foundation and the Nuffield Trust suggested that under present models of staffing there will be as many as 250,000 vacant NHS posts by 2030, rising from the current 100,000.
 

November 15, 2018
Matt Hancock made the comments during a five-hour cabinet meeting discussing the Brexit deal negotiated with the EU by Prime Minister Theresa May, according to The Times

The UK's health minister told cabinet members he could not guarantee there would be no deaths if Britain exits the European Union (EU) without a deal, The Times newspaper has reported.
 
Matt Hancock made the comments during a five-hour cabinet meeting discussing the Brexit deal negotiated with the EU by Prime Minister Theresa May, according to the newspaper.
 

November 14, 2018
My pharmacy story: Royal Pharmaceutical Society English Pharmacy Board chair Sandra Gidley

Sandra Gidley has more than two decades of experience as a community pharmacist. 
 
As a former Liberal Democrat MP for Romsey – a post she held between 2000 and 2010 – she is now the chair of the Royal Pharmaceutical Society’s (RPS) English Pharmacy board.
 
She talks to Léa Legraien about her political career, success and why the Government needs to invest more into community pharmacy.
 

November 9, 2018
Diabetes prescriptions cost NHS over £1bn a year, data reveals

NHS England spends over £1bn per year on diabetes prescriptions, data has revealed.
 
A report published yesterday (8 November) by NHS Digital showed that the cost of prescriptions for diabetes has grown by £422m in a decade, reaching more than £1bn in 2017/18.
 

November 8, 2018
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine

Jazz Pharmaceuticals plc has announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for routine use on the National Health Service (NHS) in England and Wales.
 

November 8, 2018
UK building ‘refrigeration capacity’ in case of Brexit drug shortages

The UK's health secretary has said that the Government is building extra "refrigeration capacity" in case a no-deal Brexit leaves the country short of certain medicines.
 
Speaking to ITV’s Peston show, Matt Hancock urged patients not to stockpile medicines, and said the Government is working with the pharmaceutical industry to ensure patients are able to obtain necessary medication.
 

November 7, 2018
Olarpip could provide effective treatment for brain tumours, charity reveals

An ovarian cancer drug could be an effective treatment for a difficult-to-treat type of brain tumour, research by a cancer charity has revealed.
 
Olaparib could leak through the blood brain barrier to treat glioblastoma – a condition which many other drugs have failed to treat – according to a study presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool on Monday (5 November).
 

November 5, 2018
Easier access to medical cannabis in UK will only benefit a ‘few people’, says NHS England

New legislation making it easier to access medical cannabis will only benefit a few patients, NHS England has said.
 

November 2, 2018
Make vegetarian and vegan alternatives to vaccines, charity urges

There should be vegetarian and vegan alternatives to medicines such as vaccines, a charity has said.
 

October 31, 2018
Researchers make breakthrough on sexually transmitted bacterium

Scientists have discovered the mechanism by which a bacterium adheres to human cells, which is essential for the onset of bacterial infection and disease development.
 
The researchers from the Molecular Biology Institute of Barcelona (IBMB) and the Institute of Biotechnology and Biomedicine (IBB) studied the bacterium mycoplasma genitalium (Mgen) and how it adheres to human cells.
 
They found the mechanism by which it interacts with cells, which the researchers hope will lead to new treatments to fight the infection.
 

October 31, 2018
Scientists discover source for counteracting drug resistance in tumour cells

Researchers have discovered a way of re-sensitising tumour cells that are resistant to cancer drugs.
 
The study, conducted by biologists at the University of California in San Diego, found that a human gene known as Schlafen 11 controls the sensitivity of tumour cells to DNA-damaging agents, which make up most of the widely used cancer drugs.
 

October 29, 2018
Medicines watchdog seizes over £2m counterfeit medicines in UK drugs bust

More than £2m worth of falsified medicines have been seized in the UK in less than three weeks, the Government’s medicines watchdog has revealed.
 
The Medicines and Healthcare products Regulatory Agency (MHRA) said on Wednesday (24 October) that it intercepted one million doses of counterfeit medicines worth over £2m between 9 and 27 October including diazepam, modafinil and dermal fillers.
 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine